A Point-of-Care Prediction Tool for Recurrent Tuberculosis
Open Access
- 8 July 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , e612-e622
Abstract
Background: An estimated 10% of tuberculosis (TB) survivors who recently completed treatment in India develop TB again. We sought to develop a parsimonious model for predicting TB recurrence that can help target post-treatment active case finding among the highest-risk TB survivors. Methods: The TB Aftermath trial enrolled TB survivors at treatment completion from 6 public TB clinics in Maharashtra, India, and assessed participants at 6-month intervals. Our prediction endpoint was recurrent TB diagnosed within 18 months of treatment completion. Candidate variables included risk factors for recurrence identified a priori and lung function assessments. We used LASSO (Least Absolute Shrinkage and Selection Operator) regression to shortlist predictors and estimated probability of recurrence using logistic regression. We conducted internal validation, assessed discrimination, and plotted calibration. Model selection was based on practical utility and predictive accuracy. For our selected model, we identified a cutoff for achieving 90% sensitivity. Results: Among 1033 participants, we identified 85 (8.2%) recurrences. Several 5-item models measurable at treatment completion had moderate discrimination. Our selected model included sex, household income, body mass index, peak expiratory flow from spirometry, and history of multiple TB episodes. The selected model had a cross-validated c-statistic of .69 (95% CI: .56–.77) and acceptable calibration (intercept: .03 [95% CI: −.03, .09]; slope: .66 [.08–1.24]). TB survivors with a predicted probability ≥3.7% accounted for 90% of recurrences. Conclusions: A 5-item tool, measurable at treatment completion, showed moderate predictive accuracy for recurrent TB. At scale, a simple 5-item prediction tool may increase efficiency of post-treatment active case finding.Keywords
Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI143748)
- National Institute of Allergy and Infectious Diseases (F31AI183564)
This publication has 33 references indexed in Scilit:
- Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017–19: a multistage, cluster-based, cross-sectional surveyThe Lancet Infectious Diseases, 2022
- Diabetes Mellitus and Tuberculosis Treatment Outcomes in Pune, IndiaOpen Forum Infectious Diseases, 2021
- India’s syndemic of tuberculosis and COVID-19BMJ Global Health, 2020
- Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling studyThe Lancet Global Health, 2018
- Peak flow meter with a questionnaire and mini-spirometer to help detect asthma and COPD in real-life clinical practice: a cross-sectional studynpj Primary Care Respiratory Medicine, 2017
- Defining the Needs for Next Generation Assays for TuberculosisThe Journal of Infectious Diseases, 2015
- Patients with Previously Treated Tuberculosis No Longer NeglectedClinical Infectious Diseases, 2007
- Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatmentThe Lancet, 2006
- Two Brief Alcohol-Screening Tests From the Alcohol Use Disorders Identification Test (AUDIT)Archives of internal medicine (1960), 2003
- Relapse in Persons Treated for Drug‐Susceptible Tuberculosis in a Population with High Coinfection with Human Immunodeficiency Virus in New York CityClinical Infectious Diseases, 2001